查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1990114

电脑辅助药物发现市场：按分子类型、导入模式、定价模式、类型、技术、应用和最终用户划分——2026-2032年全球市场预测

Computer-aided Drug Discovery Market by Molecule Type, Deployment Model, Pricing Model, Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

电脑辅助药物发现市场预计到 2025 年将达到 44.9 亿美元，到 2026 年将成长到 49 亿美元，到 2032 年将达到 88 亿美元，复合年增长率为 10.08%。

主要市场统计数据
基准年 2025 44.9亿美元
预计年份：2026年 49亿美元
预测年份 2032 88亿美元
复合年增长率 (%) 10.08%

人工智慧驱动的整合工作流程、云端规模资料平台和跨学科伙伴关係正在加速药物候选物的识别，并改变转化决策。

先进计算技术、大规模生物数据集和演算法创新的融合，正引领药物发现进入一个新时代。计算方法不再是孤立的任务，而是成为贯穿整个流程的关键驱动因素，影响目标选择、先导化合物筛选、先导化合物优化以及临床前安全性评估。因此，各机构正在重新思考如何设计药物发现工作流程、组建团队以及建立外部伙伴关係，以更快地产生假设并进行更具预测性的In Silico评估。

物理建模、衍生设计和分子模拟精确度的提高，正在策略性地重新定义早期药物发现的限制，并推动探索新的治疗方式。

电脑辅助药物发现领域正经历一场变革，其驱动力既来自功能的提升，也来自不断发展的产业实践。机器学习架构和基于物理的建模技​​术的进步提高了In Silico预测的可解释性和可靠性，使研究团队能够更有信心地确定实验的优先顺序。同时，可互通资料标准和联邦学习方法的普及降低了多机构合作的门槛，同时保障了资料隐私和来源资讯的安全。

检验美国关税政策在 2025 年对药物研发领域供应链动态、计算工具采购和国际合作的累积影响。

到了2025年，美国实施的贸易政策措施对电脑辅助药物发现生态系统内的采购、部署和全球合作模式产生显着影响。关税及相关贸易措施加强了对专用硬体和软体供应链的审查，促使各机构重新评估供应商关係，并考虑关键计算资产的本地化策略。这种重新评估正在影响总体拥有成本、计划进度以及跨境研究倡议的灵活性。

从细分市场的角度深入了解分子类型、部署模型、定价结构、最终用户、解决方案类型、底层技术和应用主导的部署模式。

一套精细的细分框架揭示了产品和服务实施的不同面向如何影响能力部署和价值获取。基于分子类型，生物製剂和小分子药物之间有明显的差异，二者对计算的需求截然不同。生物製剂的工作流程着重于序列分析、结构建模和免疫抗原性预测，而小分子药物计画则优先考虑配体-蛋白质相互作用、理化性质优化和合成可行性评估。这些不同的需求导致了技术组合和团队组成的多样性。

区域分析重点关注美洲、欧洲、中东和非洲以及亚太地区的趋势，这些趋势会影响人才流动、监管协调和基础设施投资重点。

区域趋势对电脑辅助药物发现能力的演进产生了决定性影响，每个区域都有独特的优势和限制因素，这些因素共同塑造了策略规划。在美洲，生物製药研究中心的集中、创业投资的便利性以及技术供应商的密集生态系统正在加速先进运算平台的普及应用。这种环境有利于加速商业化进程，并促进药物发现团队与转化开发伙伴之间的紧密合作。

本报告着重分析塑造产业格局的平台差异化、服务组合、伙伴关係和智慧财产权策略，并探讨竞争对手和合作伙伴的发展趋势。

在电脑辅助药物发现领域，企业行为呈现产品差异化、平台整合和策略伙伴关係的特征。主要企业正着力打造整合式资料管理、建模引擎和视觉化工具的平台，进而降低跨领域团队采用电脑辅助方法的门槛。同时，一些企业则专注于生成化学、高精度分子动力学或专业ADMET预测模组等细分领域的能力，以满足特定领域的需求并建立自身强大的专业知识。

为产业领导者提供实用建议，优先考虑职能投资、合作模式、管治结构和人才策略，以建立永续的竞争优势。

产业领导者在将基于计算化学的药物发现流程整合到核心研发中时，应采取务实且循序渐进的方法。优先投资解决转化研究中的直接瓶颈，例如提高ADMET性质的预测准确性以及加强标靶检验流程。为确保计算结果的持续可靠性，应将这些投资与管治框架结合，该框架要求结果可重复、模型文檔化以及定期与实验结果进行回测。

一种透明的跨学科调查方法，说明了资料来源、专家检验、建模技术以及为确保可重复性和分析严谨性而采取的措施。

本研究采用跨学科调查方法，结合了专家的访谈、二手文献的整合以及对代表性工具和工作流程的技术评估。一手资料包括与药物研发科学家、平台工程师和采购专家的结构化对话，这些对话构成了对采用障碍、管治实践和组织准备进行判断的基础。二级资讯来源包括同行评审文献、预印本和行业白皮书，从而对技术能力和预测性能方面的证据进行了多方面的检验。

这份简明扼要的结论结合了策略见解、风险因素和前瞻性考虑，旨在帮助组织应对快速发展的电脑辅助药物发现生态系统。

总而言之，电脑辅助药物发现已从一套辅助工具发展成为一项策略支柱，重塑了假设的生成、优先排序和检验。机器学习、分子模拟和数据工程等领域的技术进步，结合可靠的实验检验，提高了预测准确性并降低了转换风险。那些将管治、人才和筹资策略与这些能力结合的组织，将更有利于加速药物发现週期并提高资源配置效率。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按分子类型分類的电脑辅助药物发现市场

  • 生物製药
  • 低分子化合物

第九章：电脑辅助药物发现市场：依部署模式划分

  • 基于云端的
  • 现场

第十章：电脑辅助药物发现市场：依定价模式

  • 计量收费
  • 永久许可
  • 订阅

第十一章：电脑辅助药物发现市场：按类型划分

  • 服务
    • 咨询
    • 执行
    • 研究外包
    • 支援和维护
  • 软体
    • 数据分析
    • De Novo 设计
    • 分子建模
      • 基于配体的设计
      • 基于结构的设计
    • QSAR建模
    • 虚拟筛检

第十二章：电脑辅助药物发现市场：依技术划分

  • ADMET预测
  • 生物资讯学
    • 功能基因体学
    • 序列分析
  • 化学资讯学
    • 图书馆设计
    • QSAR建模
    • 滑板跳跃
  • De Novo 设计
  • 分子建模

第十三章：电脑辅助药物发现市场：按应用领域划分

  • 临床试验支持
  • 发现铅
  • 先导药物最适化
  • 临床前开发
  • 目标识别

第十四章：电脑辅助药物发现市场：依最终使用者划分

  • 学术机构及政府机构
  • 生技公司
  • 合约研究机构
  • 製药公司

第十五章：电脑辅助药物发现市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：电脑辅助药物发现市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：电脑辅助药物发现市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国电脑辅助药物发现市场

第十九章：中国的电脑辅助药物发现市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Accelrys, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim International GmbH
  • Chemical Computing Group Inc.
  • Dassault Systemes SE
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-5D693B46C018

The Computer-aided Drug Discovery Market was valued at USD 4.49 billion in 2025 and is projected to grow to USD 4.90 billion in 2026, with a CAGR of 10.08%, reaching USD 8.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.49 billion
Estimated Year [2026] USD 4.90 billion
Forecast Year [2032] USD 8.80 billion
CAGR (%) 10.08%

How integrated AI-driven workflows, cloud-scale data platforms, and cross-disciplinary partnerships are accelerating candidate identification and transforming translational decision-making in drug discovery

The convergence of advanced computation, large-scale biological datasets, and algorithmic innovation is ushering in a new era for drug discovery. Computational methods are no longer confined to isolated tasks; they have become integral, end-to-end enablers that influence target selection, hit identification, lead optimization, and preclinical safety evaluation. As a result, organizations are rethinking how discovery workflows are designed, how teams are arranged, and how external partnerships are structured to take advantage of faster hypothesis generation and more predictive in silico evaluations.

This report synthesizes contemporary practice and emergent capabilities in computer-aided drug discovery, focusing on how methodologies, deployment choices, and enterprise behaviors collectively shape translational outcomes. The narrative emphasizes evidence-based developments such as greater fidelity in molecular simulations, the maturation of generative chemistry approaches, and the expanding role of cloud-scale compute in enabling iterative experimentation. By connecting technological capabilities to organizational implications, the intent is to equip research leaders and business executives with a clear framework for prioritizing investments and collaborations. Through careful analysis of technology trends, commercial behaviors, and regulatory touchpoints, the report frames where competitive advantage is likely to arise and what operational changes will be required to capture it.

Strategic emergence of physics-based modeling, generative design, and expanded molecular simulation fidelity that are redefining early discovery constraints and enabling novel modality exploration

The landscape of computational drug discovery is undergoing transformative shifts driven by both capability enhancements and evolving industry practices. Advances in machine learning architectures and physics-informed modeling have improved the interpretability and reliability of in silico predictions, enabling teams to prioritize experiments with greater confidence. Concurrently, the proliferation of interoperable data standards and federated learning approaches is reducing the friction of multi-institutional collaboration while preserving data privacy and provenance.

Organizationally, there is a clear pivot from siloed algorithmic experiments toward integrated discovery platforms that span biology, chemistry, and safety. This shift has prompted new partnership archetypes: long-term platform partnerships that embed vendor tools into internal workflows, and short-term specialist engagements that accelerate specific programs. Funding patterns and internal governance have also adapted, with entities establishing centres of excellence to manage model governance, reproducibility, and ethical use of data. These shifts collectively reduce time-to-decision and increase the likelihood that computational hypotheses translate into viable experimental programs.

Importantly, the technology maturation has broadened modality exploration; biologics and small molecules alike benefit from improved design tools. As a result, organizations are increasingly blending traditional medicinal chemistry expertise with computational scientists, creating hybrid teams that can both generate and validate complex hypotheses. This holistic realignment of skills, tools, and processes marks a fundamental change in how discovery programs are conceived and executed.

Examining cumulative effects of United States tariff policies in 2025 on supply chains, computational tool sourcing, and international collaboration dynamics within drug discovery

In 2025, trade policy actions introduced by the United States have had measurable implications for the procurement, deployment, and global collaboration patterns within computational drug discovery ecosystems. Tariffs and related trade measures have increased scrutiny over supply chains for specialized hardware and software, prompting organizations to reassess vendor relationships and consider localization strategies for critical computational assets. This reassessment has implications for total cost of ownership, project timelines, and the agility of cross-border research initiatives.

As a consequence, some organizations prioritized strategic stockpiling of compute capacity and sought multi-sourcing agreements to mitigate disruption risk. Others accelerated migration to cloud providers with distributed footprints to preserve access to GPU and TPU resources despite tariff-driven uncertainty. In parallel, international collaborations adapted by shifting contractual terms, redefining responsibilities for hardware provision, and embracing standardized containerization to ease replication across jurisdictions.

On the innovation front, tariff-related pressures encouraged tighter attention to software portability and open standard adoption, as teams aimed to avoid vendor lock-in that could be exacerbated by geopolitical trade frictions. Regulatory compliance and export controls also gained prominence in procurement decisions, with legal and compliance functions becoming active participants in technology evaluation. These cumulative effects have reshaped procurement strategies and collaborative models across the discovery ecosystem, reinforcing resilience as a central criterion for technology selection.

Segment-level intelligence into molecule types, deployment models, pricing structures, end users, solution types, enabling technologies, and application-driven adoption patterns

A nuanced segmentation framework reveals how different dimensions of offering and adoption influence capability deployment and value capture. Based on molecule type, differentiation emerges between biologics and small molecules with distinct computational requirements: biologics workflows emphasize sequence analysis, structural modeling, and immunogenicity prediction, whereas small molecule programs prioritize ligand-protein interactions, physicochemical property optimization, and synthetic accessibility assessments. These divergent needs drive varied technology mixes and team structures.

Based on deployment model, choices between cloud-based and on-premises delivery shape scalability and data governance trade-offs. Cloud-based approaches facilitate burst compute and collaborative federated learning, while on-premises deployments remain attractive for organizations with strict data residency or security constraints. Based on pricing model, organizations select between pay-per-use, perpetual license, and subscription arrangements to align financial exposure with project tempo and budget predictability.

Based on end user, adoption patterns differ across academic and government institutes, biotechnology companies, contract research organizations, and pharmaceutical companies, each prioritizing different combinations of flexibility, depth of customization, and regulatory alignment. Based on type, offerings split into services and software. Services encompass consulting, implementation, research outsourcing, and support and maintenance, providing hands-on expertise and operational integration. Software splits into data analytics, de novo design, molecular modeling, QSAR modeling, and virtual screening, with molecular modeling further divided into ligand-based design and structure-based design, reflecting the need for both top-down and bottom-up computational strategies.

Based on technology, capabilities include ADMET prediction, bioinformatics, chemoinformatics, de novo design, and molecular modeling. Within bioinformatics there is emphasis on functional genomics and sequence analysis, while chemoinformatics covers library design, QSAR modeling, and scaffold hopping. Based on application, use cases such as clinical trials support, lead discovery, lead optimization, preclinical development, and target identification illustrate how technology stacks are mapped to specific translational objectives. These segmentation lenses together inform where investments will yield the highest strategic return and how vendors can tailor their value propositions to distinct customer archetypes.

Regional intelligence highlighting Americas, Europe Middle East and Africa, and Asia-Pacific dynamics influencing talent flows, regulatory alignment, and infrastructure investment priorities

Regional dynamics critically influence the evolution of computational drug discovery capabilities, with each geography presenting distinct strengths and constraints that shape strategic planning. In the Americas, concentration of biopharma research centers, access to venture capital, and a dense ecosystem of technology vendors promote rapid adoption of advanced computational platforms. This environment supports accelerated commercialization pathways and close ties between discovery teams and translational development partners.

In Europe, Middle East & Africa, regulatory harmonization efforts and strong academic-industrial collaborations foster rigorous validation practices and a focus on reproducibility. Investment patterns in this region often emphasize public-private partnerships and infrastructure that supports precompetitive data sharing. These features contribute to robust methodological standards and collaborative networks that underpin long-term capability building.

In Asia-Pacific, rapid expansion of research infrastructure, significant public sector investment in biotechnology, and a growing pool of computational talent create an environment conducive to large-scale data initiatives and high-throughput screening programs. This region increasingly becomes a hub for both contract research activity and end-to-end discovery programs, leveraging cost efficiencies and scaling advantages. Across regions, differences in regulatory regimes, talent availability, and infrastructure maturity inform where organizations choose to centralize or decentralize capabilities, and those choices in turn shape partnership strategies and operational models.

Competitive and collaborative company insights focusing on platform differentiation, service portfolios, partnerships, and intellectual property strategies shaping the industry landscape

Company behavior in the computational discovery space is characterized by a mix of product differentiation, platform bundling, and strategic partnerships. Leading firms emphasize integrated platforms that combine data management, modeling engines, and visualization tools to lower the barrier for multidisciplinary teams to adopt computational approaches. Others focus on niche capabilities-such as generative chemistry, high-fidelity molecular dynamics, or specialized ADMET prediction modules-to serve domain-specific needs and develop defensible expertise.

Partnerships between software vendors and contract research organizations or laboratory automation providers are increasingly common, enabling end-to-end workflows that connect in silico hypothesis generation with rapid experimental validation. Intellectual property strategies often center on proprietary model architectures and curated datasets that provide predictive advantage, while open-source contributions and community benchmarks play a role in driving adoption and improving model transparency.

Service providers differentiate through consulting capabilities that translate algorithmic outputs into experimental plans, and through implementation teams that embed tools into existing discovery pipelines. Across the competitive landscape, companies that demonstrate interoperability, strong evidence of predictive performance, and a commitment to rigorous validation tend to secure longer-term engagements. Strategic alliances with academic institutions, clinical networks, and data custodians further expand access to curated datasets that enhance model training and validation, reinforcing a virtuous cycle of capability improvement for those organizations able to navigate complex partnership ecosystems.

Actionable recommendations for industry leaders to prioritize capability investments, partnership models, governance frameworks, and talent strategies for sustainable competitive advantage

Industry leaders should adopt a pragmatic, phased approach to integrating computational discovery into core R&D. First, prioritize capability investments that address immediate translational bottlenecks, such as improving prediction of ADMET properties or strengthening target validation pipelines. Align these investments with a governance framework that mandates reproducibility, model documentation, and routine back-testing against experimental outcomes to ensure sustained confidence in computational outputs.

Second, cultivate hybrid talent models that embed computational scientists alongside medicinal chemists and biologists to ensure hypotheses are both computationally sound and experimentally tractable. Invest in internal training programs and cross-functional rotations to accelerate knowledge transfer and reduce dependency on external consultants. Third, pursue partnership models that balance strategic platform commitments with the flexibility of specialist engagements, thereby preserving the ability to pilot new approaches while securing long-term integration where it delivers clear operational benefits.

Fourth, adopt procurement and architecture choices that mitigate geopolitical and supply chain risks, including multi-cloud strategies, software portability, and contractual clauses for continuity of service. Fifth, implement metrics and dashboards that translate computational performance into experimental productivity measures, thereby enabling continuous improvement and clearer ROI conversations with stakeholders. Together, these recommendations form an actionable roadmap for organizations aiming to derive consistent, reproducible value from computational drug discovery investments.

Transparent multidisciplinary research methodology describing data sources, expert validation, modeling approaches, and steps taken to ensure reproducibility and analytical rigor

This study employs a multidisciplinary research methodology combining primary expert interviews, secondary literature synthesis, and technical evaluation of representative tools and workflows. Primary inputs include structured conversations with discovery scientists, platform engineers, and procurement specialists, which informed judgment on adoption barriers, governance practices, and organizational readiness. Secondary sources encompassed peer-reviewed literature, preprints, and industry white papers to triangulate technological capabilities and evidence of predictive performance.

Technical evaluations involved reproducibility checks on benchmark datasets, assessment of model explainability features, and review of integration capabilities with laboratory information management systems and automation platforms. Wherever possible, findings were validated with case examples that illustrate how specific computational approaches impacted experimental throughput or decision-making processes. Ethical considerations and data governance practices were explicitly examined to ensure recommendations are implementable within prevailing regulatory regimes.

Analytical rigor was maintained through documented methodologies for data collection, transparent criteria for inclusion of tools and vendors in the study, and cross-validation of qualitative inputs. Limitations and assumptions are clearly articulated to support appropriate interpretation of conclusions and to enable organizations to adapt the approach to their unique contexts. This structured methodology ensures that the report's insights are both evidence-based and operationally relevant.

Concluding synthesis summarizing strategic takeaways, risk factors, and forward-looking considerations for organizations navigating a rapidly evolving computational drug discovery ecosystem

In summary, computational drug discovery has transitioned from a set of supporting tools to a strategic pillar that reshapes how hypotheses are generated, prioritized, and validated. Technological advances in machine learning, molecular simulation, and data engineering have enhanced predictive fidelity and reduced translational risk when paired with robust experimental validation. Organizations that align governance, talent, and procurement strategies with these capabilities are positioned to accelerate discovery cycles and increase the efficiency of resource allocation.

Key risk factors include geopolitical and trade-related perturbations to hardware and software supply chains, the potential for model overfitting without rigorous validation, and the need for clear governance around data provenance and ethical use. Nevertheless, institutions that invest in interoperable architectures, hybrid talent models, and strategic partnerships can convert these challenges into sources of resilience and competitive differentiation. The path forward requires disciplined experimentation, transparent measurement of computational performance against experimental outcomes, and a willingness to adapt organizational structures to sustain cross-disciplinary collaboration.

Ultimately, success in this evolving ecosystem will be defined by the ability to integrate computational insights seamlessly into laboratory decision-making, maintain reproducibility and model governance, and scale capabilities in a way that aligns with translational imperatives and regulatory expectations. This synthesis provides a foundation for executives to make informed decisions about where to focus resources and how to structure partnerships for long-term impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Computer-aided Drug Discovery Market, by Molecule Type

  • 8.1. Biologics
  • 8.2. Small Molecules

9. Computer-aided Drug Discovery Market, by Deployment Model

  • 9.1. Cloud-Based
  • 9.2. On-Premises

10. Computer-aided Drug Discovery Market, by Pricing Model

  • 10.1. Pay Per Use
  • 10.2. Perpetual License
  • 10.3. Subscription

11. Computer-aided Drug Discovery Market, by Type

  • 11.1. Services
    • 11.1.1. Consulting
    • 11.1.2. Implementation
    • 11.1.3. Research Outsourcing
    • 11.1.4. Support And Maintenance
  • 11.2. Software
    • 11.2.1. Data Analytics
    • 11.2.2. De Novo Design
    • 11.2.3. Molecular Modeling
      • 11.2.3.1. Ligand Based Design
      • 11.2.3.2. Structure Based Design
    • 11.2.4. QSAR Modeling
    • 11.2.5. Virtual Screening

12. Computer-aided Drug Discovery Market, by Technology

  • 12.1. ADMET Prediction
  • 12.2. Bioinformatics
    • 12.2.1. Functional Genomics
    • 12.2.2. Sequence Analysis
  • 12.3. Chemoinformatics
    • 12.3.1. Library Design
    • 12.3.2. QSAR Modeling
    • 12.3.3. Scaffold Hopping
  • 12.4. De Novo Design
  • 12.5. Molecular Modeling

13. Computer-aided Drug Discovery Market, by Application

  • 13.1. Clinical Trials Support
  • 13.2. Lead Discovery
  • 13.3. Lead Optimization
  • 13.4. Preclinical Development
  • 13.5. Target Identification

14. Computer-aided Drug Discovery Market, by End User

  • 14.1. Academic And Government Institutes
  • 14.2. Biotechnology Companies
  • 14.3. Contract Research Organizations
  • 14.4. Pharmaceutical Companies

15. Computer-aided Drug Discovery Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Computer-aided Drug Discovery Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Computer-aided Drug Discovery Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Computer-aided Drug Discovery Market

19. China Computer-aided Drug Discovery Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Accelrys, Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Bayer AG
  • 20.9. Bio-Rad Laboratories, Inc.
  • 20.10. Boehringer Ingelheim International GmbH
  • 20.11. Chemical Computing Group Inc.
  • 20.12. Dassault Systemes SE
  • 20.13. Eli Lilly and Company
  • 20.14. Gilead Sciences, Inc.
  • 20.15. GlaxoSmithKline PLC
  • 20.16. Merck & Co., Inc.
  • 20.17. Novartis AG
  • 20.18. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ON-PREMISES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PAY PER USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PERPETUAL LICENSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBSCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY IMPLEMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY RESEARCH OUTSOURCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DATA ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIGAND BASED DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY FUNCTIONAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SEQUENCE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LIBRARY DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SCAFFOLD HOPPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DE NOVO DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY ACADEMIC AND GOVERNMENT INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 253. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 254. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 257. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 258. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 260. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. GCC COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 290. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY DEPLOYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 292. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY PRICING MODEL, 2018-2032 (USD MILLION)
  • TABLE 293. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 295. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY MOLECULAR MODELING, 2018-2032 (USD MILLION)
  • TABLE 297. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE, BY CHEMOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 COMPUTER-AIDED DRUG DISCOVERY MARKET SIZE,